Alembic Pharmaceuticals is currently trading at Rs. 510.00, up by 5.90 points or 1.17% from its previous closing of Rs. 504.10 on the BSE.
The scrip opened at Rs. 506.00 and has touched a high and low of Rs. 511.50 and Rs. 506.00 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 469.75 on 20-Sep-2017.
Last one week high and low of the scrip stood at Rs. 517.50 and Rs. 485.00 respectively. The current market cap of the company is Rs. 9,614.00 crore.
The promoters holding in the company stood at 72.68%, while Institutions and Non-Institutions held 14.14% and 13.18% respectively.
Alembic Pharmaceuticals through its 100% owned subsidiary, Alembic Pharmaceuticals Inc., has completed acquisition of West Caldwell, New Jersey, USA based generic drug developer Orit Laboratories LLC (Orit) along with real estate, owned by Okner Realty LLC (Okner).
The acquisition increases Alembic’s US product portfolio with 7 approved ANDAs, and 4 ANDAs pending approval. The acquisition also increases Alembic’s breadth and capabilities in the US with a competent R&D team bringing complementary skill sets in soft-gelatin based oral solids and oral liquids.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1657.10 |
| Dr. Reddys Lab | 1218.45 |
| Cipla | 1230.25 |
| Zydus Lifesciences | 931.10 |
| Lupin | 2312.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: